A Phase 2, Investigator Initiated Study to Determine the Safety and Efficacy of TH-302 in Combination With Bevacizumab for Glioblastoma Following Bevacizumab Failure
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Bevacizumab (Primary) ; Evofosfamide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 07 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
- 07 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2017.
- 07 Aug 2017 Status changed from recruiting to active, no longer recruiting.